Private equity fund manager and Enterprise Investment Scheme (EIS) specialist Calculus Capital has invested a further £2.5m into diagnostics company Epistem Holdings plc (“Epistem”) via its EIS fund and Venture Capital Trust (VCT) investment vehicles. Calculus is the cornerstone investor in a £6.5m equity fundraising undertaken by Epistem. Epistem, an AIM-listed molecular diagnostics and biotechnology … Continued
John Glencross, CEO and Co-Founder, Calculus Capital, shares his views on the future for SMEs in the post-Brexit economy. There is understandable anger from those who wanted to remain, confusion about what next and mostly unhelpful comments from prominent figures on both sides. Most of the furore is irrelevant, however. The rules were clear at … Continued
Calculus Capital has today announced that the target fundraise of £25 million for EIS Fund 16 has been surpassed. EIS Fund 16 has now officially closed. John Glencross, CEO, Calculus Capital: “We are delighted to have once again hit our target fundraise for our 16th EIS Fund. We have a strong deal pipeline and look forward … Continued
Mark Lane from the Newcastle Chronicle looks at corporate finance trends in the North East and asks what the region’s business owners need to do to gain backing for their growth plans. Asked what they are looking for when approached for finance, a very common theme emerges from the region’s finance professionals: good management is … Continued
The Enterprise Investment Scheme Association (EISA) has appointed Mark Brownridge as its new Director General. Mark will take up the post on 1st August, joining from Mazars Financial Planning, where he is Head of Research and Development. He takes over from John Glencross, Chief Executive of Calculus Capital, who has been Acting Director General of … Continued
Private equity fund manager and Enterprise Investment Scheme specialist Calculus Capital has invested £2.4m in a new fundraising by AIM-listed portfolio company Scancell Holdings plc. Calculus’s latest funding contributed to a total of £6.2m raised this month by Scancell. Scancell develops therapeutic immunotherapy vaccine platforms for the treatment of cancers and the funding will be used … Continued
Private equity fund manager and Enterprise Investment Scheme specialist Calculus Capital has invested £2.25m in an Imperial College spin-out that has developed emissions detection technologies used to monitor air pollution in major cities and industrial centres around the world. Duvas Technologies (“Duvas”) produces equipment that enables remote sensing and identification of airborne chemicals and gases … Continued
Calculus Capital portfolio company Chop’d has announced an expansion in their trial with Costa Coffee. Whitbread-owned Costa Coffee will expand its offering with premium salad operator Chop’d to a further 12 London stores following a trial launched in six sites last summer. The roll-out will lead to the fresh food company’s jerk chicken, tuna niçoise, feta and … Continued
John Glencross, CEO, Calculus Capital shares his views on the latest changes to EIS & VCT regulation. The past year has seen the most significant changes to EIS and VCT legislation since first introduced by Kenneth Clarke in 1994. The key changes are well known. The prohibition on VCTs and EIS Funds buying existing businesses … Continued
John Glencross, CEO, Calculus Capital is quoted in a piece run by Investment Week. How do VCTs and EIS compare for retirement planning? Amid concern Chancellor George Osborne plans to announce further changes to the pensions tax relief system in the Budget next month, managers reveal how holding VCTs and EIS within retirement portfolios could … Continued